Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (September 2008)

37 slides from Auxilium Pharmaceuticals's investor presentation, Sep 24, 2008

  1. Slide 1: September 2008

    Exhibit 99.1 September 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma

  3. Slide 3: Slide 3

  4. Slide 4: Auxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 33

  5. Slide 5: Anticipated News Flow Events

    Anticipated News Flow Events 5 6 6 Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events End of 2009: • XIAFLEX- Results of Peyronie's Phase IIb Study H109: • XIAFLEX- Open Label Dupuytren’s Contracture Safety Data Early 2009: • XIAFLEX- File BLA for Dupuytren's Contracture Early 2010 XIAFLEX – FDA

  6. Slide 6: XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • Worldwide rights offer opti

  7. Slide 7: Dupuytren's Contracture—a Debilitating Condition

    Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery may be reser

  8. Slide 8: Current Treatment Options Are Invasive or Ineffective

    Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

  9. Slide 9: Dupuytren's Contracture—Unmet Medical Need

    Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among adult Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients

  10. Slide 10: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  11. Slide 11: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  12. Slide 12: CORD I Design

    CORD I Design CORD I Design • Largest ever double-blind, placebo-controlled trial in Dupuytren’s contracture – randomized in 2:1 ratio of active to placebo – enrolled a 2:1 ratio of MP:PIP – enrolled 1:1 ratio of less severe to more severe joints • Primary endpoint is reduction in contracture to wit

  13. Slide 13: Primary Endpoint Outcome Compares Favorably To Surgery

    Primary Endpoint Outcome Compares Favorably To Surgery Primary Endpoint Outcome Compares Favorably To Surgery

  14. Slide 14: 4 Out Of 5 Dupuytren's Contracture Patients Improved By 50%

    4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50% > 4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50%

  15. Slide 15: Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture

    Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture

  16. Slide 16: XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications

    XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Serious Adverse Events Number Rate/Inj. Tendon / Ligament*: Confirmed Tendon Rupture 0.14% Ligament Injury 0.05% Total Tendon /

  17. Slide 17: CORD I Key Takeaways

    CORD I Key Takeaways CORD I Key Takeaways • Primary endpoint of 5° reached in 64% of patients (p<0.001) – 25 of 26 endpoints met with statistical significance of <0.001, 1 of 26 was met with a p-value = 0.002 – Of the 73 patients who didn’t respond, 44 received less than 3 injections and 25 had no p

  18. Slide 18: Dupuytren's Commercial Opportunity

    Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag

  19. Slide 19: At least 240,000 Dupuytren's Candidates In U.S. & Europe Annually

    At least 240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 X

  20. Slide 20: Expected Pathway to BLA Filing in Early 2009

    Expected Pathway to BLA Filing in Early 2009 Expected Pathway to BLA Filing in Early 2009 • Complete 12 month open-label safety follow up from >100 CORD I patients originally randomized to XIAFLEX • Complete open-label CORD II and JOINT I/II trials to attain 1,000 patient exposure data • Finalize BL

  21. Slide 21: Peyronie's Disease—a Devastating Disorder

    Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt

  22. Slide 22: Epidemiology—Peyronie's Disease

    Epidemiology—Peyronie’s Disease Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at in adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is years • High association with other diseases such a

  23. Slide 23: Current Treatment—Surgical

    Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K

  24. Slide 24: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Reported Success

    Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener

  25. Slide 25: Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation

    Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation > Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Mon

  26. Slide 26: Peyronie's Phase IIb Study Enrolling Patients

    Peyronie’s Phase IIb Study Enrolling Patients Peyronie’s Phase IIb Study Enrolling Patients • Study designed to assess the safety and efficacy of XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – ~11 U.S. sites • Patie

  27. Slide 27: Peyronie's Phase IIb Study Design

    Peyronie’s Phase IIb Study Design Peyronie’s Phase IIb Study Design • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling. no Placebo D no XIAFLEX C yes Placebo B yes XIAFLEX A Targeted Number of Patients Plaque Modeling S

  28. Slide 28: Peyronie's Phase IIb Patient Reported Outcome (PRO)

    Peyronie’s Phase IIb Patient Reported Outcome (PRO) Peyronie’s Phase IIb Patient Reported Outcome (PRO) • Study is also designed to validate a proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week peri

  29. Slide 29: At least 210,000 Peyronie's Candidates In U.S. and Europe Annually

    At least 210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates or 67% of Medical/ Surgical candidates

  30. Slide 30: Testim is the Fastest Growing Testosterone Replacement Therapy Gel

    Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45

  31. Slide 31: 447% +30%

    447% +30%

  32. Slide 32: Gels Fastest Growing TRT Segment

    Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Jun 2008 L12M: 22.8+% Gel Segment Growth ($) Gel Segment Growth ($) Ju

  33. Slide 33: Testim quarterly net revenues and scripts: Established Track Record of Consistent Growth

    Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth $- $5 $10 $15 $20 $25 $30 $35 Net Revs TRX ® ($ in millions) Established Track Record of Consistent Growth Q2 2008 Net Revenues Y/Y Growth: +32.4% Q2 2008 Net Q2 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growt

  34. Slide 34: We Believe Testim Is Driving Growth in Overall Gel Market

    We Believe Testim Is Driving Growth in Overall Gel Market Testim Share of TRx of Gel Market Source: IMS data *July 2008 gel market share of decile 8 - 10 PCPs (29.9%)* gel market share of decile 8 - 10 Urologists (41.9%)* 22.0% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% Mar-03 Aug-08

  35. Slide 35: 2Q08 Financial Results and 2008 Guidance ($ Millions)

    2Q08 Financial Results and 2008 Guidance ($ Millions) Q2 ’08 1H’08 Guidance Revenues $30.9 $58.0 $120-125 R&D Expense $13.4 $26.6 $52-56 SG&A Expense $22.2 $43.2 $88-92 Net Loss ($11.7) ($24.0) ($44-48) Stock – Based Comp Expense $2.8 $4.9 $9-11 Cash & cash equivalents $48.8 2Q08 Financial Results a

  36. Slide 36: Strategic Priorities

    Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – File Dupuytren’s BLA in early 2009 – Complete enrollment in Phase IIb in Peyronie’s Disease in Q1 2009 – Continue market research activities; prepare commercial team – Continue development of XIAFLEX in Pey

  37. Slide 37: Slide 37

Auxilium Pharmaceuticals — Investor Presentation (September 2008) on 6ix